Tecentriq (atezolizumab) - Roche
Tecentriq: "Tecentriq + nab-paclitaxel was well tolerated, with no cumulative toxicities and no new or late-onset safety signals"; Metastatic triple negative breast cancer (Roche) - Jun 4, 2019 - ASCO 2019: "Although not formally testable due to the pre-specified statistical analysis plan, updated median OS improvement from 18 to 25 months was observed in the PD-L1+ population (HR 0.71)" 
P3 data
https://www.roche.com/dam/jcr:b8bc8bc9-e9cd-4548-8187-c94a3e3fc008/en/irp20190603.pdf
 
Jun 4, 2019
 
 
a40360c2-5426-4136-8bd4-235d5da656e3.jpg

52277dc2-a721-489d-869d-49328d76e53a.jpg